Detalhe da pesquisa
1.
Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.
Blood
; 118(22): 5872-82, 2011 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-21908434
2.
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
Am J Hematol
; 84(5): 268-72, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19296472
3.
Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment.
Sci Rep
; 9(1): 14189, 2019 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31578352
4.
Calmodulin kinase II inhibition disrupts cardiomyopathic effects of enhanced green fluorescent protein.
J Mol Cell Cardiol
; 44(2): 405-10, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18048055
5.
Preclinical animal models of multiple myeloma.
Bonekey Rep
; 5: 772, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26909147
6.
Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling.
J Bone Miner Res
; 28(4): 960-9, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23172686
7.
Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.
Cancer Res
; 72(9): 2183-9, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22374979
8.
Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.
PLoS One
; 7(11): e48871, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23173040
9.
Inhibition of TGF-ß signaling by 1D11 antibody treatment increases bone mass and quality in vivo.
J Bone Miner Res
; 25(11): 2419-26, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20499365
10.
A murine model of myeloma that allows genetic manipulation of the host microenvironment.
Dis Model Mech
; 2(11-12): 604-11, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19779066
11.
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
Blood
; 111(5): 2833-42, 2008 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18094333